Kelessis Nickos G, Vassilopoulos Pericles P, Bai Mary P, Agnantis Niki J, Avital Shmuel R, Rosenthal Raul J
1st Surgical Department, Saint-Savvas Anticancer Hospital, Athens.
Anticancer Res. 2002 Nov-Dec;22(6B):3457-63.
Primary gastric non-Hodgkin's lymphoma is a well-defined clinicopathological entity with a distinct histological spectrum and indolent course. Its optimal management still remains controversial. In this study we present our experience with surgery being part of the multimodal treatment and we compare our results with those referred to in the world literature.
Sixty-five patients (37 males, 28 females) with gastric MALT lymphoma were retrospectively analyzed. Forty-seven patients underwent curative resection, eleven received chemotherapy as primary treatment, two patients received radiotherapy before any other treatment and five patients received combined chemo-radiation therapy.
For the early stages of the disease (I-III), radical resection offered a two-year survival rate of 100% and 93%, respectively, and a five-year survival of 85% and 67%, respectively. For those stage I patients, who were managed surgically followed by adjuvant therapy, the two- and five-year survival was 90% and 78%, respectively. For stage II patients for whom chemo-radiation therapy followed surgery, the two- and five-year survival was 88% and 65%, respectively.
In view of the results of our study, surgery is an adequate treatment modality for the early stages of the disease. The addition of radiotherapy or chemotherapy does not improve the overall survival. Conversely, for the advanced stages (II2-IV), primary chemotherapy is the best treatment option with surgery being reserved for cytoreduction or chemo-radiotherapy-induced complications.
原发性胃非霍奇金淋巴瘤是一种明确的临床病理实体,具有独特的组织学谱和惰性病程。其最佳治疗方案仍存在争议。在本研究中,我们介绍了手术作为多模式治疗一部分的经验,并将我们的结果与世界文献中提及的结果进行比较。
对65例胃黏膜相关淋巴组织淋巴瘤患者(37例男性,28例女性)进行回顾性分析。47例患者接受了根治性切除,11例患者接受了化疗作为初始治疗,2例患者在接受任何其他治疗前接受了放疗,5例患者接受了联合放化疗。
对于疾病的早期阶段(I - III期),根治性切除的两年生存率分别为100%和93%,五年生存率分别为85%和67%。对于那些接受手术治疗后再进行辅助治疗的I期患者,两年和五年生存率分别为90%和78%。对于手术后接受放化疗的II期患者,两年和五年生存率分别为88%和65%。
鉴于我们的研究结果,手术是疾病早期阶段的一种充分治疗方式。放疗或化疗的加入并不能提高总体生存率。相反,对于晚期阶段(II2 - IV期),初始化疗是最佳治疗选择,手术则留作减瘤或放化疗引起的并发症的处理手段。